Today, the American Diabetes Association® (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO) published a joint consensus report addressing diabetes management in chronic kidney disease (CKD). A joint writing group of ADA and KDIGO representatives reviewed and developed a series of consensus statements that provide clear direction for implementation of care to improve clinical outcomes for people with diabetes and CKD. The organizations aligned in areas of CKD screening and diagnosis, glycemia monitoring, lifestyle therapies, treatment goals, and pharmacologic management.
“It is compelling that we now have a general agreement between diabetologists and nephrologists on how to diagnose and treat diabetic kidney disease in its early stages to markedly delay progression,” said co-author George Bakris, director of the Comprehensive Hypertension Center at the University of Chicago, Illinois. “This is a message for primary care physicians, and like any report, it should be translated by the caregiver to the patient so that both parties can agree on a common approach.”
“This report is all the more necessary given the recent advances in the field and dramatic public health toll that CKD poses,” added Robert Gabbay, MD, PhD, chief scientifc and medical officer of the ADA. People with diabetes and CKD are at high risk for kidney failure, atherosclerotic cardiovascular disease, heart failure, and premature mortality. The report provides specific guidance on:
- Renin-angiotensin system inhibitors
- Metformin
- Sodium–glucose cotransporter 2 inhibitors
- Glucagon-like peptide 1 receptor agonists
- Nonsteroidal mineralocorticoid receptor antagonist
Read the full consensus report from Diabetes Care® ahead of the final print and online issue.
# # #
,
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation’s leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 82 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 133 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).
About KDIGO
KDIGO is a Belgian foundation committed to developing and implementing nephrology guidelines that improve patient outcomes on a global basis. KDIGO is independent, volunteer-led, self-managed, and accountable to the public and the patients it serves. Learn More.
